Once approved, here is what the pricing landscape looks like based on comparable drugs: Semaglutide (Wegovy) without insurance runs $1,300 to $1,600 per month in the US Tirzepatide (Zepbound) without insurance runs $1,000 to $1,300 per month in the US Retatrutide, as a next-generation triple agonist, will likely land at $1,200 to $1,800 per month at launch In Australia, the UK, and Canada, prices tend to be lower due to government drug pricing controls
Analysis BC, ID, DS, AL and TDC
TRT patients with persistent low libido A common scenario: testosterone levels are optimized but desire hasn't fully returned
Understanding peptide legality in your jurisdiction is also important before proceeding
The clinical trial averages provide useful benchmarks, but individual results depend on several modifiable and non-modifiable factors